1
|
Li Z, Zhu Y, Li C, Trinh R, Ren X, Sun F, Wang Y, Shang P, Wang T, Wang M, Morrison SL, Zhang J. Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer. Oncoimmunology 2017; 6:e1290038. [PMID: 28405526 DOI: 10.1080/2162402x.2017.1290038] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Revised: 01/25/2017] [Accepted: 01/26/2017] [Indexed: 12/11/2022] Open
Abstract
Interferon-α (IFNα) has multiple antitumor effects including direct antitumor toxicity and the ability to potently stimulate both innate and adaptive immunity. However, its clinical applications in the treatment of malignancies have been limited because of short half-life and serious adverse reactions when attempting to deliver therapeutically effective doses. To address these issues, we fused IFNα2a to the anti-vascular endothelial growth factor and receptor 2 (VEGFR2) antibody JZA00 with the goal of targeting it to the tumor microenvironment where it can stimulate the antitumor immune response. The fusion protein, JZA01, is effective against colorectal cancer by inhibiting angiogenesis, exhibiting direct cytotoxicity, and activating the antitumor immune response. Although JZA01 exhibited reduced IFNα2 activity in vitro compared with native IFNα2, VEGFR2 targeting permitted efficient antiproliferative, proapoptotic, antiangiogenesis, and immune-stimulating effects against the colorectal tumors HCT-116 and SW620. JZA01 showed in vivo efficacy in NOD-SCID mice-bearing established HCT-116 tumors. In conclusion, this study describes an antitumor immunotherapy that is highly promising for the treatment of colorectal cancer.
Collapse
Affiliation(s)
- Zhaoting Li
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| | - Yijia Zhu
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| | - Chenchen Li
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| | - Ryan Trinh
- Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles , Los Angeles, CA, USA
| | - Xueyan Ren
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| | - Fumou Sun
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| | - Youfu Wang
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| | - Pengzhao Shang
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| | - Tong Wang
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| | - Min Wang
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| | - Sherie L Morrison
- Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles , Los Angeles, CA, USA
| | - Juan Zhang
- Antibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China
| |
Collapse
|
2
|
Igaz P. Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials. Orv Hetil 2014; 155:1908-12. [DOI: 10.1556/oh.2014.30048] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Due to their inhibitory effects on hormone secretion, somatostatin analogues are of pivotal importance in the symptomatic treatment of hormone-secreting neuroendocrine tumours. Although several earlier clinical observations supported the view that these biological agents are capable of inhibiting the growth of neuroendocrine tumours, the PROMID study published in 2009 was the first to confirm the inhibitory effect of octreotide on tumour growth and demonstrated the prolongation of progression free survival. These findings have been confirmed and extended by the most recent CLARINET trial with lanreotide published in 2014. Somatostatin analogues are capable of inhibiting tumour growth and stabilizing disease irrespective of the hormonal activity of the tumour and, therefore, their applicability is expected to be extended to the treatment of hormonally inactive neuroendocrine tumours, as well. Orv. Hetil., 2014, 155(48), 1908–1912.
Collapse
Affiliation(s)
- Péter Igaz
- Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
| |
Collapse
|